# Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)

> **NCT02980523** · PHASE2 · COMPLETED · sponsor: **Laboratorios Sophia S.A de C.V.** · enrollment: 150 (actual)

## Conditions studied

- Bacterial Conjunctivitis

## Interventions

- **DRUG:** PRO-157
- **DRUG:** Vigamox
- **DRUG:** Zymar®
- **DRUG:** Lagricel Ofteno®

## Key facts

- **NCT ID:** NCT02980523
- **Lead sponsor:** Laboratorios Sophia S.A de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-06
- **Final completion:** 2017-05
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2019-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980523, "Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02980523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*